Nanofármacos

LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF

Resumen de: AU2023391361A1

Provided are aerosolized pharmaceutical compositions including aerosol particles, the aerosol particles comprising lipid nanoparticles (LNPs). Also provided herein are liquid pharmaceutical compositions for use in making aerosolized pharmaceutical compositions. Also provided herein are methods of administering the aerosolized pharmaceutical compositions. Also provided herein are kits including a lipid nanoparticle composition including one or more of a phospholipid, an ionizable lipid, a PEG-lipid, a sterol.

NANOPARTICLE DISPERSIONS COMPRISING THERAPEUTIC AGENTS

Resumen de: AU2023385865A1

Disclosed herein are dense nanolipid fluid (DNLF) dispersions comprising desirable characteristics for incorporating bioactive agents such as peptides into lipid phase of the dispersion for biodelivery of the agents for their typical purpose. Continuous methods for preparing the DNLF dispersions are also disclosed herein to include formation of a crude mill base and passing the base through a twin screw extruder. Dispersions disclosed herein can express a particle size of less than 150 nm under stable storage conditions, while forming lamellar structures after exposure to heat and/or evaporation of the aqueous components of the dispersion.

MICROCAPSULES AND ENCAPSULATION THEREOF

Resumen de: CN119698325A

The present invention relates to microcapsules based on a polymeric shell and a lipophilic active core material with improved thermal stability.

COMPOSITIONS OF NANOPARTICLES FOR TREATMENT OF NEUROPATHIC PAIN

Resumen de: AU2023313035A1

The invention concerns a novel and innovative composition for the treatment of neuropathic pain (NP). Specifically, the invention concerns HfO

NANOPARTICLES AND PEPTIDES FOR THE DELIVERY OF CARGOS TO CHONDROCYTES

Resumen de: WO2024023361A1

Nanoparticles suitable for delivery of a cargo to a chondrocyte, and targeting peptides comprising a chondrocyte targeting sequence, are provided. Further provided are uses of the nanoparticles and targeting peptides, for example, in treating a joint or cartilage disease or disorder.

COMPOSITIONS OF NANOPARTICLES FOR TREATMENT OF NEUROPATHIC PAIN

Resumen de: AU2023313035A1

The invention concerns a novel and innovative composition for the treatment of neuropathic pain (NP). Specifically, the invention concerns HfO

LOADED EXTRACELLULAR VESICLE

Resumen de: WO2024023504A1

The present invention relates to compositions comprising an extracellular vesicle (EV). In particular, the extracellular vesicle (EV) comprises a single pass EV transmembrane protein fused to a moiety on the surface of the EV and/or a cargo molecule. The composition may be used to deliver the cargo molecule. Methods of manufacturing the composition are also provided.

LIPID NANOPARTICLE COMPOSITIONS COMPRISING SURFACE LIPID DERIVATIVES AND RELATED USES

Resumen de: WO2024026482A1

The present disclosure provides lipid assemblies suitable for delivery of therapeutic agents to hematopoietic stem and progenitor cells (HSPCs), wherein the lipid assemblies comprise a neutral polymer surface lipid. The present disclosure also provides therapeutic and diagnostic uses related to the lipid assemblies.

LIPID NANOPARTICLE COMPOSITIONS COMPRISING PHOSPHOLIPID DERIVATIVES AND RELATED USES

Resumen de: WO2024026487A1

The present disclosure provides lipid assemblies suitable for delivery of therapeutic agents to hematopoietic stem and progenitor cells (HSPCs), wherein the lipid assemblies comprise a phosphatidylserine phospholipid. The present disclosure also provides therapeutic and diagnostic uses related to the lipid assemblies.

LIPID NANOPARTICLES FOR DRUG DELIVERY AND METHODS OF USE THEREOF

Resumen de: WO2024030865A2

Disclosed are compositions, systems, and methods involving lipid nanoparticle primarily composed of phosphatidic acid (PA), monogalactosyldiacylglycerol (MGDG), and digalactosyldiacylglycerol (DGDG). In particular, the PA, MGDG, and DGDG are present in the nanoparticles in useful ratios, preferably falling in a ratio of 3 to 7, 1 to 3, and 2 to 4, respectively. Further, it is useful for the PA, MGDG, and DGDG to make up 90% or more of the total lipid in the nanoparticles. The disclosed lipid nanoparticles are useful as drug delivery systems for delivery of a drug, such as oral delivery, intravascular delivery, or intramuscular delivery. The disclosed lipid nanoparticles can be used in methods involving administration or delivery of the nanoparticles to a subject. In some forms, the subject can be a disease or condition, such as inflammatory bowel disease, ulcerative colitis, Crohn's disease, cancer, colon cancer, or a coronavirus infection.

SILICA MESOPOROUS NANOPARTICLES AND USE THEREOF FOR CAPTURING IMMUNOGLOBULINS

Resumen de: EP4563528A1

The present invention relates to a silica mesoporous nanoparticle comprising a covalently bound protein G' or protein A, the composition comprising said nanoparticle, the use thereof for capturing, purifying, eliminating and/or isolating immunoglobulins, preferably IgG, as well as a method for purifying an immunoglobulin, methods for pre-treating samples in order to subsequently diagnose allergies, infections and/or autoimmune diseases in a patient, and said diagnostic methods.

LIPID NANOPARTICLE AND PHARMACEUTICAL COMPOSITION

Resumen de: EP4563142A1

The present invention relates to lipid nanoparticles capable of delivering a target substance to hepatic stellate cells. The lipid nanoparticles are for delivering a target substance to hepatic stellate cells and comprise a pH-sensitive cationic lipid including a hydrophilic portion and two hydrophobic portions, wherein an acid dissociation constant pKa of a lipid membrane constituting the lipid nanoparticles is greater than or equal to 6.7 and less than 8.2.

LIPID NANOPARTICLES FOR IMMUNOTHERAPY

Resumen de: WO2024026029A2

Disclosed are compositions and methods related to lipid nanoparticles (LNPs) comprising ionizable lipids. The LNPs can comprise nucleic acid sequences encoding therapeutic peptides for immunotherapy, for example, bispecific antibodies or antigen binding fragments thereof.

METHODS AND COMPOSITIONS FOR USING LEUCINE ZIPPERS FOR CROSSLINKING OF CELLS AND DRUG CARRIERS

Resumen de: WO2024026444A1

Non-invasive, in situ forming depots for delivery of a therapeutic agents, containing heterodimerizing, synthetic leucine zippers for physical crosslinking mediated by competition-based dimerization. The heterodimerizing, synthetic leucine zippers form a self-assembling depot of the therapeutic agent at a target site in vivo. A library of such heterodimerizing, synthetic leucine zippers is provided, as well as methods of treating subjects using the same.

一种具有T细胞激活能力的聚合物脂质杂化纳米颗粒及其应用

Resumen de: CN120078737A

本发明提供了一种具有T细胞激活能力的聚合物脂质杂化纳米颗粒，其特征在于，包括阳离子聚合物，辅助脂质，胆固醇和聚乙二醇衍生脂质，所述阳离子聚合物包括由聚乙烯亚胺和对甲苯磺酰基精氨酸制备得到的共聚物。本发明提供的聚合物脂质杂化纳米颗粒具有T细胞激活和转染的双重能力，能够实现一步激活和转染原代T细胞，大大缩短了制备周期，减少了制备的复杂性。此外，通过所述聚合物脂质杂化纳米颗粒RT LNP递送CAR mRNA产生的CAR‑T细胞在体外具有优异的细胞杀伤能力，并能够特异性分泌杀伤性细胞因子，实现对与靶细胞的特异性高效性杀伤，验证了本发明中开发的聚合物脂质杂化纳米颗粒是一个快速生产mRNA CAR T细胞产品的有前途的平台。

IGF1-BP偶联脂质纳米颗粒及其制备方法与应用

Resumen de: CN120078905A

本发明涉及IGF1‑BP偶联脂质纳米颗粒及其制备方法与应用，属于生物医药技术领域。为解决现有子痫前期预防及治疗中仍缺少针对子宫内膜的纳米载体及相应的靶向药物的问题，本发明提供了IGF1‑BP偶联脂质纳米颗粒的制备方法，分别配制有机相溶液和水相溶液，以有机相溶液和水相溶液组装脂质纳米颗粒，再通过EDC/NHS技术将IGF1‑BP通过偶联反应连接到脂质纳米颗粒表面，得到IGF1‑BP偶联脂质纳米颗粒。本发明提供的IGF1‑BP偶联脂质纳米颗粒将降低子宫内膜APOD表达的吗啉代寡核苷酸靶向递送到子宫内膜组织，不仅能够在孕期缓解子痫前期的症状，还能够对子痫前期高风险的产妇在孕前期做到预防性治疗。

序贯靶向纳米药物及其制备方法和在心肌缺血再灌注损伤中的应用

Resumen de: CN120078739A

本发明涉及一种序贯靶向纳米药物及其制备方法和在心肌缺血再灌注损伤中的应用，属于纳米药物技术领域。本发明的序贯靶向纳米药物包括：通道黑色素纳米胶囊及封装在通道黑色素纳米胶囊上的环孢霉素A；通道黑色素纳米胶囊是以聚合物微球为模板，多巴胺为原料，在碱性条件下制备得到的线粒体靶向载体。该纳米药物具有超高载药率，可控释放和超强的抗氧化活性，良好的生活相容性，可以实现对从心梗组织到心肌细胞线粒体的序贯靶向，有效保护线粒体形态和功能；能显著较少心肌细胞线粒体DNA释放，抑制cGAS‑STING信号通路激活，降低心肌组织的炎症因子水平；能显著抑制caspase3凋亡信号通路激活，减少心肌细胞凋亡。

一种具有肝靶向性的断奶仔猪免疫调节纳米颗粒及其制备方法

Resumen de: CN120078741A

本发明属于动物免疫增强剂技术领域，具体涉及一种具有肝靶向性的断奶仔猪免疫调节纳米颗粒及其制备方法，包括以下步骤：S1、向去离子水中加入半乳甘露聚糖，搅拌溶解后加入丁基甘油酯，调整pH在保护气下反应，反应结束后透析纯化后冻干得到丁基甘油酯修饰的半乳甘露聚糖；S2、将S1制备的丁基甘油酯修饰的半乳甘露聚糖溶解在缓冲液中，搅拌至溶解后向其中滴加水飞蓟宾乙醇溶液，超声反应得到水飞蓟宾‑半乳甘露聚糖自组装纳米颗粒；S3、向水飞蓟宾‑半乳甘露聚糖自组装纳米颗粒中加入交联剂，交联反应后透析纯化、冷冻干燥制得免疫调节纳米颗粒。本发明以水飞蓟宾为免疫调节剂，基于半乳甘露聚糖与断奶仔猪肝脏枯否细胞及树突细胞表面甘露糖受体的天然识别特性，并利用丁基甘油酯疏水特性增强半乳甘露聚糖对水飞蓟宾的纳米封装效率及其稳定性，构建一种具有断奶仔猪肝靶向性的新型免疫调节剂。

一种可电离阳离子脂质化合物及其应用

Resumen de: CN120081891A

本发明提供了一种具有式(I)所示结构的可电离阳离子脂质化合物，其可用于制备用于递送治疗剂和/或预防剂的脂质纳米颗粒(LNP)。利用本发明的可电离阳离子脂质化合物制备的LNP具有较佳的稳定性和转染效率，可以高效地、稳定地将生物活性物质(包括核酸，例如mRNA)递送至靶细胞或器官，从而在体内引起高特异性抗体应答。#imgabs0#

多肽复合物、蛋白、核酸、组合物及其用途

Resumen de: CN120081947A

一种多肽复合物、蛋白、核酸、组合物及其用途。采用细胞特异性高表达和长滞留(ePR)策略，以使肝星状细胞中的特异性mRNA过表达成治疗蛋白，并促使治疗蛋白长期锚定在纤维化的基质微环境中。确定了含有羧基的一代、二代视黄醇衍生物，能够在类脂质纳米粒(LNP)中部分替代胆固醇，通过静脉注射，富集在纤维化区域，使纤维化肝脏中mRNA表达提升约10倍。此外，通过将胶原蛋白结合结构域(CBD)的基因序列与治疗蛋白的C末端偶联，对治疗性mRNA进行了工程设计。在筛选中，发现胎盘生长因子(PLGF)的肽序列显示出最强的胶原亲和力，能够延长过表达治疗蛋白的肝脏滞留时间，并将全身副作用降至最低。

用于治疗癌症的组合物和方法

Resumen de: AU2023343598A1

Compounds, compositions, uses, and methods for reducing cell viability of a cancer cell, or for preventing or treating cancer, are provided herein. In certain examples, methods for reducing cell viability of a cancer cell and/or for preventing or treating cancer in a subject in need thereof are provided which may include a step of treatment with a GDP-bound form of Rab1a (Rab1a

一种具有免疫调节和抑制肝癌细胞的负载阿霉素的人参硒多糖纳米载体的制备方法

Resumen de: CN120078742A

本发明公开了一种具有免疫调节和抑制肝癌细胞的负载阿霉素的人参硒多糖纳米载体的制备方法，要解决抗肿瘤药物阿霉素导致组织和器官的毒性损伤以及存在免疫系统的抑制的问题。本发明通过将脱氧胆酸接枝在人参硒多糖上，使其疏水化并形成两亲性多糖聚合物，克服了人参硒多糖分子量大和生物利用度低等局限性。以自组装人参硒多糖纳米粒为抗肿瘤药物递送的载体，不仅具有免疫调节作用能有效改善抗肿瘤药物引起的免疫抑制等副作用；还具备pH敏感响应释放特性，从而增强药物在肿瘤区域的靶向效果，这一创新性载体具备良好的临床应用前景。

一种AMD3100固核脂质纳米粒及其应用

Resumen de: CN120078735A

本发明公开了一种AMD3100固核脂质纳米粒及其应用。本发明提供了一种固核脂质纳米粒，其包括DOPA改性的磷酸钙内核、DSPE‑PEG2000‑AMD3100、DSPE‑PEG2000、胆固醇和DOTAP；所述DSPE‑PEG2000‑AMD3100的结构如式I所示；所述DOPA改性的磷酸钙内核中，所述DOPA负载于所述磷酸钙内核表面。本发明将AMD3100作为递药载体的靶头修饰于固核脂质纳米粒载体上，有助于将大量的治疗性药物递送至缺血区域的受损细胞及新生细胞，实现缺血脑区的靶向药物递送，提高药物治疗效果。#imgabs0#

一种用于肿瘤免疫治疗的巨噬细胞特异性RNA编辑的聚合物纳米系统

Resumen de: CN120082029A

本发明涉及肿瘤免疫治疗领域，尤其涉及一种用于巨噬细胞特异性RNA编辑的纳米聚合物系统及其应用。该系统能够通过靶向巨噬细胞上的吞噬检查点，通过RNA编辑增强肿瘤相关巨噬细胞的吞噬功能，并在体内调节抗肿瘤免疫反应。我们还证明了该MAGE系统在多种小鼠肿瘤模型(包括基于人源患者肿瘤异种移植的胰腺腺癌模型)中的治疗效果。为体内递送RNA编辑工具至巨噬细胞提供了一个有前景的平台。

一种仿生小胶质细胞膜包覆的ZnS@BSA纳米颗粒及其制备方法和应用

Nº publicación: CN120078743A 03/06/2025

Solicitante:

苏州大学附属第二医院

Resumen de: CN120078743A

本发明提供了一种仿生小胶质细胞膜包覆的ZnS@BSA纳米颗粒及其制备方法和应用，属于生物纳米材料技术领域。本发明采用自组装方法，通过将醋酸锌和硫氢化钠与牛血清白蛋白(BSA)混合，合成了牛血清白蛋白的硫化锌纳米颗粒(ZnS@BSA)。由于BSA对金属离子具有亲和力以及延长半衰期的特性，可被广泛应用于纳米医学中。本发明利用挤压法制备了仿生小胶质细胞膜包覆的ZnS@BSA纳米颗粒(ZnS@BSA@MM)，ZnS@BSA@MM增强了牛血清白蛋白的硫化锌纳米颗粒在损伤部位的积累，并减少了血液循环中硫化氢的损失，促进了功能性神经元再生，抑制了神经瘢痕形成，并改善了SCI小鼠的运动功能恢复。